Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy

Clinical Endocrinology

Volumn 67, Issue 3, 2007, Pages 426-433

  Colao, Annamaria ^a   Di Sarno, Antonella ^a   Guerra, Ermelinda ^a   Pivonello, Rosario ^a   Cappabianca, Paolo ^a   Caranci, Ferdinando ^a   Elefante, Andrea ^a   Cavallo, Luigi M ^a   Briganti, Francesco ^a   Cirillo, Sossio ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CORTISONE ACETATE; ESTROGEN; GESTAGEN; LEVOTHYROXINE; PROLACTIN; RECOMBINANT GROWTH HORMONE; TESTOSTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPERPROLACTINEMIA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OBSERVATIONAL METHOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; ROC CURVE; STATISTICAL SIGNIFICANCE; TUMOR VOLUME;

ADULT; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; HYPERPROLACTINEMIA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROLACTINOMA; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; REMISSION INDUCTION; ROC CURVE; SEX DISTRIBUTION; TIME FACTORS; YOUNG ADULT;

EID: 34548032098     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02905.x     Document Type: Article

References (41)

1. Gillam, M.P., Molitch, M.E., Lombardi, G. Colao, A. (2006) Advances in the treatment of prolactinomas. Endocrine Reviews, 27, 485 534.
2. Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Ismail, I. Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine, 331, 904 909.
3. Biller, B.M., Molitch, M.E., Vance, M.L., Cannistraro, K.B., Davis, K.R., Simons, J.A., Schoenfelder, J.R. Klibanski, A. (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Journal of Clinical Endocrinology and Metabolism, 81, 2338 2343.
4. Delgrange, E., Maiter, D. Donckier, J. (1996) Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. European Journal of Endocrinology, 134, 454 456.
5. Ferrari, C.I., Abstract, R., Bevan, J.S., Brabant, G., Ciccarelli, E., Motta, T., Mucci, M., Muratori, M., Musatti, L., Verbessem, G. Scanlon, M.F. (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clinical Endocrinology, 46, 409 413.
6. Colao, A., Di Sarno, A., Landi, M.L., Cirillo, S., Sarnacchiaro, F., Facciolli, G., Pivonello, R., Cataldi, M., Merola, B., Annunziato, L. Lombardi, G. (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. Journal of Clinical Endocrinology and Metabolism, 82, 3574 3579.
7. Colao, A., Di Sarno, A., Sarnacchiaro, F., Ferone, D., Di Renzo, G., Merola, B., Annunziato, L. Lombardi, G. (1997) Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Journal of Clinical Endocrinology and Metabolism, 82, 876 883.
8. Muratori, M., Arosio, M., Gambino, G., Romano, C., Biella, O. Faglia. G. (1997) Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation, 20, 537 546.
9. Verhelst, J., Abstract, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., Mahler, C., Stevenaert, A., Verlooy, J., Raftopoulos, C. Beckers, A. (1999) Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients. Journal of Clinical Endocrinology and Metabolism, 84, 2518 2522.
10. Cannavò, S., Curtò, L., Squadrito, S., Almoto, B., Vieni, A. Trimarchi, F. (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenomas. Journal of Endocrinological Investigation, 22, 354 359.
11. Pontikides, N., Krassas, G.E., Nikopoulou, E. Kaltsas, T. (2000) Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas. Pituitary, 2, 277 281.
12. Colao, A., Di Sarno, A., Landi, M.L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L. Lombardi, G. (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Journal of Clinical Endocrinology and Metabolism, 85, 2247 2252.
13. Di Sarno, A., Landi, M.L., Cappabianca, P., Di Salle, F., Rossi, F.W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G. Colao, A. (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinaemia: prevalence, clinical definition, and therapeutic strategy. Journal of Clinical Endocrinology and Metabolism, 86, 5256 5261.
14. Colao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S. Lombardi, G. (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Journal of Clinical Endocrinology and Metabolism, 89, 1704 1711.
15. De Rosa, M., Zarrilli, S., Vitale, G., Di Somma, C., Orio, F., Tauchmanovà, L., Lombardi, G. Colao, A. (2004) Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. Journal of Clinical Endocrinology and Metabolism, 89, 621 625.
16. Schlechte, J.A., Sherman, B.M., Chapler, F.K. van Gilder, J. (1985) Long-term follow-up of women with surgically treated prolactin-secreting pituitary tumors. Journal of Clinical Endocrinology and Metabolism, 62, 1296 1301.
17. Bevan, J.S., Adams, C.B.T., Burke, C.W., Morton, K.E., Molyneux, A.J., Moore, R.A. Esiri, M.M. (1987) Factors in the outcome of trans-sphenoidal surgery for prolactinoma and non-functioning pituitary tumor, including preoperative bromocriptine therapy. Clinical Endocrinology, 26, 541 556.
18. Losa, M., Mortini, P., Barzaghi, R., Gioia, L. Giovanelli, M. (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. Journal of Clinical Endocrinology and Metabolism, 87, 3180 3186.
19. Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R. Lombardi, G. (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinaemia. New England Journal of Medicine, 349, 2023 2033.
20. Johnston, D.G., Prescott, R.W.G., Kendall-Taylor, P., Hall, K., Crombie, A.L., Hall. R., McGregor, A., Watson, M.J. Cook, D.B. (1983) Hyperprolactinaemia. Long-term effects of bromocriptine. American Journal of Medicine, 75, 868 874.
21. Johnston, D.G., Hall, K., Kendall-Taylor, P., Patrick, D., Watson, M. Cook, D.B. (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerized tomography. Lancet, 2, 187 192.
22. Bergh, T., Nillius, S.J. Wide, L. (1982) Menstrual function and prolactin levels after long-term bromocriptine treatment of prolactinaemic amenorrhea. Clinical Endocrinology, 16, 587 593.
23. Maxons, W.S., Dudzinski, M., Handwerger, S.H. Hammond, C.B. (1984) Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertility and Sterility, 41, 218 223.
24. Zarate, A., Canales, E.S., Cano, C. Pilonieta, C.J. (1983) Follow-up of patients with prolactinoma after discontinuation of long-term therapy with bromocriptine. Acta Endocrinologica (Copenhagen), 104, 139 142.
25. Moriondo, P., Travaglini, P., Nissim, M., Conti, A. Faglia, G. (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. Journal of Clinical Endocrinology and Metabolism, 60, 764 772.
26. Winkelmann, W., Allolio, B., Deuss, U., Heesen, D. Kaulen, D. (1985) Persisting normoprolactinemia after withdrawal of bromocriptine long-term therapy in patients with prolactinomas. In : MacLeod, R.M., Thorner, M.O., Scapagnini, U. eds. Prolactin. Basic and Clinical Correlates. Liviana Press, Padova, 817 822.
27. Wang, C., Lam, K.S.L., Ma, T.C., Chan, T., Liu, M.Y. Yeung, R.T.T. (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clinical Endocrinology, 27, 363 371.
28. Passos, V.Q., Souza, J.J.S., Musolino, N.R.C. Bronstein, M.D. (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. Journal of Clinical Endocrinology and Metabolism, 87, 3578 3582.
29. Biswas, M., Smith, J., Jadon, D., McEwan, P., Rees, D.A., Evans, L.M., Scanlon, M.F. Davies, J.S. (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clinical Endocrinology, 63, 26 31.
30. Van't Verlaat, J.W. Croughs, R.J. (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumor size. Clinical Endocrinology, 34, 175 178.
31. Di Sarno, A., Landi, M.L., Marzullo, P., Di Somma, C., Pivonello, R., Cerbone, G., Lombardi, G. Colao, A. (2000) The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clinical Endocrinology, 53, 53 60.
32. Schlechte, J., Dolan, K., Sherman, B., Chapler, F. Luciano, A. (1989) The natural history of untreated hyperprolactinaemia: a prospective analysis. Journal of Clinical Endocrinology and Metabolism, 68, 412 418.
33. Sisam, D.A., Sheehan, J.P. Sheeler, L.R. (1987) The natural history of untreated microprolactinomas. Fertility and Sterility, 48, 67 71.
34. Crosignani, P.G., Mattei, A.M., Severini, V., Cavioni, V., Maggioni, P. Testa, G. (1992) Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. European Journal of Obstetrics & Gynecology and Reproductive Biology, 44, 175 180.
35. Karunakaran, S., Page, R.C. Wass, J.A. (2001) The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clinical Endocrinology, 54, 295 300.
36. Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. Tourniaire, J. (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism, 82, 2102 2107.
37. Pinzone, J.J., Katznelson, L., Danila, D.C., Pauler, D.K., Miller, C.S. Klibanski, A. (2000) Primary medical therapy of micro- and macroprolactinomas in men. Journal of Clinical Endocrinology and Metabolism, 85, 3053 3057.
38. Corsello, S.M., Ubertini, G., Altomare, M., Lovicu, R.M., Migneco, M.G., Rota, C.A. Colosimo, C. (2003) Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology, 58, 662 670.
39. Ciccarelli, A., Guerra, E., De Rosa, M., Milone, F., Zarrilli, S., Lombardi, G. Colao, A. (2005) PRL-secreting adenomas in male patients. Pituitary, 8, 39 42.
40. De Rosa, M., Ciccarelli, A., Zarrilli, S., Guerra, E., Gaccione, M., Di Sarno, A., Lombardi, G. Colao, A. (2006) The treatment with cabergoline for 24 months normalizes the quality of seminal fluid in hyperprolactinaemic males. Clinical Endocrinology, 64, 307 313.
41. Colao, A., Di Sarno, A., Cappabianca, P., Briganti, F., Pivonello, R., Di Somma, C., Faggiano, A., Biondi, B. Lombardi, G. (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinaemia. European Journal of Endocrinology, 148, 325 331.